IJSER Home >> Journal >> IJSER
International Journal of Scientific and Engineering Research
ISSN Online 2229-5518
ISSN Print: 2229-5518 2    
Website: http://www.ijser.org
scirp IJSER >> Volume 3,Issue 2,February 2012
Tamoxifen: A Novel Approach for the Treatment of Estrogen Receptor Negative Cancer
Full Text(PDF, )  PP.229-235  
Eun Be Kim, Judith Jacobson, Donna Leonardi
- Burkitt’s Lymphoma, Estrogen Receptor, Inhibitor, Mammalian target of rapamycin, Protein Kinase C, Ramos, Tamoxifen
Tamoxifen is a selective estrogen receptor modulator that is used to treat estrogen receptor positive cancers, specifically breast cancer. Tamoxifen antagonizes the estrogen receptor and thus impedes estrogen induced growth of cancer cells. However, recent studies have shown that tamoxifen also inhibits protein kinase C (PKC), a protein that activates the PKC/ Akt/ PI3k pathway. Disrupting this pathway results in the inhibition of the downstream target of the PKC/ Akt/ PI3k pathway, mTOR, a protein that promotes cell survival and growth. The aim of this project was to determine the inhibitory activity of tamoxifen on an estrogen receptor negative (ER-) cell line, specifically a Burkitt's lymphoma cell line, Ramos. Enzyme immunosorbent assays were used to measure activities of PKC and mTOR. The MTS assay was used to measure Ramos cell viability after tamoxifen treatment (1-25µM). Results showed that Ramos cell viability, PKC activity, and mTOR activity each decreased with statistical significance demonstrating a dose-response relationship (p < 0.05) after tamoxifen treatment (1-25µM). Tamoxifen may therefore have potential as a treatment for not just ER positive cancers, but cancers that have a constitutively activated PKC/PI3k/Akt pathway.
Untitled Page